23.70

3.00% 0.69

After Hours: 23.71 0.01 +0.04%

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $23.70, with a volume of 1.05M. It is up +3.00% in the last 24 hours and up +7.87% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Previous Close:

$23.01

Open:

$23.06

24h Volume:

1.05M

Relative Volume:

0.89

Market Cap:

$2.97B

Revenue:

$247.00M

Net Income/Loss:

$-353.00M

P/E Ratio:

-7.1812

EPS:

-3.3003

Net Cash Flow:

$-484.00M

1W Performance:

+4.64%

1M Performance:

+7.87%

6M Performance:

+40.24%

1Y Performance:

+195.88%

1-Day Range:

$22.61

$23.87

1-Week Range:

$22.07

$23.87

52-Week Range:

$7.06

$26.40

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

601

Twitter

@arcusbio

Next Earnings Date

2024-12-06

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	23.70	2.88B	247.00M	-353.00M	-484.00M	-3.3003
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-13-26	Upgrade	Goldman	Neutral → Buy
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Apr 13, 2026

RSI Check: What is Arcus Biosciences Incs valuation compared to sectorWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Apr 13, 2026

Risks Report: Whats Arcus Biosciences Incs historical returnMarket Movement Recap & High Return Trade Guides - baoquankhu1.vn

Apr 13, 2026

Sell Signal: Can Arcus Biosciences Inc withstand a market correctionVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn

Apr 06, 2026

Pharma News: Can Arcus Biosciences Inc keep up with sector leadersQuarterly Investment Review & Community Consensus Trade Signals - baoquankhu1.vn

Apr 06, 2026

Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - MSN

Apr 06, 2026

Apr 04, 2026

RCUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

RCUS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026